155 related articles for article (PubMed ID: 27448772)
1. Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).
Muraoka T; Ide M; Morikami K; Irie M; Nakamura M; Miura T; Kamikawa T; Nishihara M; Kashiwagi H
Bioorg Med Chem; 2016 Sep; 24(18):4206-4217. PubMed ID: 27448772
[TBL] [Abstract][Full Text] [Related]
2. Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).
Muraoka T; Ide M; Irie M; Morikami K; Miura T; Nishihara M; Kashiwagi H
Chem Pharm Bull (Tokyo); 2016; 64(11):1622-1629. PubMed ID: 27803473
[TBL] [Abstract][Full Text] [Related]
3. Structure-guided development of covalent TAK1 inhibitors.
Tan L; Gurbani D; Weisberg EL; Hunter JC; Li L; Jones DS; Ficarro SB; Mowafy S; Tam CP; Rao S; Du G; Griffin JD; Sorger PK; Marto JA; Westover KD; Gray NS
Bioorg Med Chem; 2017 Feb; 25(3):838-846. PubMed ID: 28011204
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.
Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Eigenbrot C; Gallion S; Johnson AR; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Wang X; Wong H; Xiong JM; Xu J; Yu C; Zhao Z; Currie KS
Bioorg Med Chem Lett; 2016 Jan; 26(2):575-579. PubMed ID: 26675441
[TBL] [Abstract][Full Text] [Related]
6. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Tan L; Gurbani D; Weisberg EL; Jones DS; Rao S; Singer WD; Bernard FM; Mowafy S; Jenney A; Du G; Nonami A; Griffin JD; Lauffenburger DA; Westover KD; Sorger PK; Gray NS
Bioorg Med Chem; 2017 Feb; 25(4):1320-1328. PubMed ID: 28038940
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.
Hornberger KR; Chen X; Crew AP; Kleinberg A; Ma L; Mulvihill MJ; Wang J; Wilde VL; Albertella M; Bittner M; Cooke A; Kadhim S; Kahler J; Maresca P; May E; Meyn P; Romashko D; Tokar B; Turton R
Bioorg Med Chem Lett; 2013 Aug; 23(16):4511-6. PubMed ID: 23856049
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223
[TBL] [Abstract][Full Text] [Related]
9. Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Katz JD; Haidle A; Childers KK; Zabierek AA; Jewell JP; Hou Y; Altman MD; Szewczak A; Chen D; Harsch A; Hayashi M; Warren L; Hutton M; Nuthall H; Su HP; Munshi S; Stanton MG; Davies IW; Munoz B; Northrup A
Bioorg Med Chem Lett; 2017 Jan; 27(1):114-120. PubMed ID: 27816515
[TBL] [Abstract][Full Text] [Related]
10. A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase.
Scarneo SA; Hughes PF; Yang KW; Carlson DA; Gurbani D; Westover KD; Haystead TAJ
J Biol Chem; 2020 Feb; 295(6):1565-1574. PubMed ID: 31914413
[TBL] [Abstract][Full Text] [Related]
11. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
13. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors.
Guo P; Xie Z; Zhang H; Zhang Z; Han C; Cheng D; Lin D; Zhang Y; Wang X; Guo X; Ye F
Med Chem; 2017; 13(8):753-760. PubMed ID: 28641527
[TBL] [Abstract][Full Text] [Related]
16. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease.
Totzke J; Gurbani D; Raphemot R; Hughes PF; Bodoor K; Carlson DA; Loiselle DR; Bera AK; Eibschutz LS; Perkins MM; Eubanks AL; Campbell PL; Fox DA; Westover KD; Haystead TAJ; Derbyshire ER
Cell Chem Biol; 2017 Aug; 24(8):1029-1039.e7. PubMed ID: 28820959
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
[TBL] [Abstract][Full Text] [Related]
18. TAK1 selective inhibition: state of the art and future opportunities.
Kilty I; Jones LH
Future Med Chem; 2015; 7(1):23-33. PubMed ID: 25582331
[TBL] [Abstract][Full Text] [Related]
19. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
[TBL] [Abstract][Full Text] [Related]
20. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Tan L; Nomanbhoy T; Gurbani D; Patricelli M; Hunter J; Geng J; Herhaus L; Zhang J; Pauls E; Ham Y; Choi HG; Xie T; Deng X; Buhrlage SJ; Sim T; Cohen P; Sapkota G; Westover KD; Gray NS
J Med Chem; 2015 Jan; 58(1):183-96. PubMed ID: 25075558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
